Table 2.

summary of the studies included in the review

Study	Duration	Drugs involved	Baseline population	Results
Pfützner et al20,21	76 weeks	saxagliptin/metformin 5/500 mg saxagliptin/metformin 10/500 mg saxagliptin 10 g/placebo metformin 500 mg/placebo.	1306 patients, 18–77 years of age with HbA1c 8.0%–12.0%.	HbA1c: −2.31% for saxagliptin/metformin 5/500 mg* −2.33% for saxagliptin/metformin 10/500 mg* −1.55% for saxagliptin 10 mg −1.79% for metformin 500 mg (*P < 0.0001 versus metformin and saxagliptin monotherapies)
Scheen et al22	18 weeks	saxagliptin 5 mg once daily as add on therapy to previously taken metformin sitagliptin 100 mg once daily as add-on therapy to previously taken metformin.	801 patients with HbA1c between 6.5%–10% on stable metformin doses (1500–3000 mg/day).	HbA1c: −0.52% for saxagliptin/metformin −0.62% for sitagliptin/metformin (P not significant)
De Fronzo et al23	24 weeks	saxagliptin 2.5 mg once daily as add on therapy to previously taken metformin saxagliptin 5 mg once daily as add on therapy to previously taken metformin saxagliptin 10 mg once daily as add on therapy to previously taken metformin placebo as add on therapy to previously taken metformin.	743 patients taking a stable dose of metformin (1.500 but not >2.550 mg/day)	HbA1c: −0.59% for saxagliptin 2.5 mg/metformin* −0.69% for saxagliptin 5 mg/metformin* −0.58% for saxagliptin 10 mg/metformin* +0.13% for placebo/metformin (*P ≤ 0.0001 versus placebo)
Goke et al24	52 weeks	saxagliptin 5 mg once daily as add on therapy to previously taken metformin glipizide up-titrated as needed from 5 to 20 mg/day as add on therapy to previously taken metformin.	858 patients on stable metformin doses ≥1500 mg/day	HbA1c: −0.74% for saxagliptin/metformin −0.80% for glipizide/metformin (P not significant) Hypoglycemia: 3% for saxagliptin/metformin* 36.3% for glipizide/metformin (*P < 0.0001 versus glipizide/metformin) Body weight: −1.1 kg for saxagliptin/metformin* +1.1 kg for with glipizide/metformin (*P < 0.0001 versus glipizide/metformin)